Navigation Links
FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
Date:12/3/2007

iovan. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Diovan to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Diovan will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Diovan could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; unexpected regulatory actions or delays or government regulation generally, and other risks and factors referred to in the Novartis AG's current Form 20-F on file with the U.S. Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, gastrointestinal and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
7. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Tropical forests affected by habitat fragmentation store less biomass and carbon dioxide 2Tropical forests affected by habitat fragmentation store less biomass and carbon dioxide 3CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2Study reveals how Arctic food webs affect mercury in polar bears 2Gentiva 28R 29 Health Services Completes Acquisition of Home Health Agency 56080 1Gentiva 28R 29 Health Services Completes Acquisition of Home Health Agency 56080 2Gentiva 28R 29 Health Services Completes Acquisition of Home Health Agency 56080 3Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 3B 241 Increase Gives State Second Highest Cigarette Tax in the Nation 56075 1Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 3B 241 Increase Gives State Second Highest Cigarette Tax in the Nation 56075 2Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 3B 241 Increase Gives State Second Highest Cigarette Tax in the Nation 56075 3Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16 2009 13807 1Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16 2009 13807 2Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16 2009 13807 3Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16 2009 13807 4